全文获取类型
收费全文 | 881篇 |
免费 | 117篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 14篇 |
妇产科学 | 35篇 |
基础医学 | 65篇 |
口腔科学 | 14篇 |
临床医学 | 67篇 |
内科学 | 204篇 |
皮肤病学 | 39篇 |
神经病学 | 22篇 |
特种医学 | 23篇 |
外科学 | 132篇 |
综合类 | 22篇 |
预防医学 | 52篇 |
眼科学 | 3篇 |
药学 | 71篇 |
肿瘤学 | 219篇 |
出版年
2022年 | 5篇 |
2021年 | 8篇 |
2020年 | 10篇 |
2019年 | 16篇 |
2018年 | 20篇 |
2017年 | 11篇 |
2016年 | 25篇 |
2015年 | 21篇 |
2014年 | 24篇 |
2013年 | 33篇 |
2012年 | 65篇 |
2011年 | 56篇 |
2010年 | 24篇 |
2009年 | 24篇 |
2008年 | 49篇 |
2007年 | 48篇 |
2006年 | 37篇 |
2005年 | 40篇 |
2004年 | 43篇 |
2003年 | 36篇 |
2002年 | 30篇 |
2001年 | 20篇 |
2000年 | 29篇 |
1999年 | 21篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 9篇 |
1993年 | 9篇 |
1992年 | 14篇 |
1991年 | 16篇 |
1990年 | 17篇 |
1989年 | 15篇 |
1988年 | 16篇 |
1987年 | 17篇 |
1986年 | 19篇 |
1985年 | 18篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 13篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1975年 | 5篇 |
1974年 | 9篇 |
1968年 | 5篇 |
1963年 | 3篇 |
排序方式: 共有999条查询结果,搜索用时 31 毫秒
51.
Debashis Sarker Rhoda Molife T R Jeffrey Evans Maryon Hardie Cheryl Marriott Priska Butzberger-Zimmerli Rosemary Morrison Judith A Fox Carla Heise Sharianne Louie Natasha Aziz Felix Garzon Glenn Michelson Ian R Judson Dalal Jadayel Edgar Braendle Johann S de Bono 《Clinical cancer research》2008,14(7):2075-2081
PURPOSE: To determine the maximum tolerated dose (MTD) dose-limiting toxicity, and pharmacokinetic and pharmacodynamic profile of TKI258 (formerly CHIR-258). EXPERIMENTAL DESIGN: A phase I dose escalating trial in patients with advanced solid tumors was performed. Treatment was initially as single daily doses on an intermittent 7-day on/7-day off schedule. Following a protocol amendment, a second schedule comprised, during cycle 1, 7-day on/7-day off treatment followed by 14 days of continuous daily dosing; subsequent cycles comprised 28 days of daily dosing. Pharmacokinetics and evaluation of phosphorylated extracellular signal-regulated kinase (ERK) in peripheral blood mononuclear cells were done during the first 28 days of each schedule. RESULTS: Thirty-five patients were treated in four intermittent (25-100 mg/d) and three continuous (100-175 mg/d) dosing cohorts. Observed drug-related toxicities were nausea and vomiting, fatigue, headache, anorexia, and diarrhea. Dose-limiting toxicities were grade 3 hypertension in one patient at 100 mg continuous dosing, grade 3 anorexia in a second patient at 175 mg, and grade 3 alkaline phosphatase elevation in a third patient at 175 mg. One patient had a partial response (melanoma) and two patients had stable disease >6 months. TKI258 pharmacokinetics were linear over the dose range of 25 to 175 mg. Five of 14 evaluable patients had modulation of phosphorylated ERK levels. CONCLUSIONS: The MTD was defined as 125 mg/d. Evidence of antitumor activity in melanoma and gastrointestinal stromal tumors warrants further investigation, and other phase I studies are ongoing. Further pharmacodynamic evaluation is required in these studies to evaluate the biological effects of TKI258. 相似文献
52.
53.
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis 总被引:29,自引:0,他引:29
Tiano HF Loftin CD Akunda J Lee CA Spalding J Sessoms A Dunson DB Rogan EG Morham SG Smart RC Langenbach R 《Cancer research》2002,62(12):3395-3401
Nonsteroidal anti-inflammatory drugs are widely reported to inhibit carcinogenesis in humans and in rodents. These drugs are believed to act by inhibiting one or both of the known isoforms of cyclooxygenase (COX). However, COX-2, and not COX-1, is the isoform most frequently reported to have a key role in tumor development. Here we report that homozygous deficiency of either COX-1 or COX-2 reduces skin tumorigenesis by 75% in a multistage mouse skin model. Reduced tumorigenesis was observed even though the levels of stable 7,12-dimethylbenz(a)anthracene-DNA adducts were increased about 2-fold in the COX-deficient mice compared with wild-type mice. The premature onset of keratinocyte terminal differentiation appeared to be the cellular event leading to the reduced tumorigenesis because keratin 1 and keratin 10, two keratins that indicate the commitment of keratinocytes to differentiate, were expressed 8-13-fold and 10-20-fold more frequently in epidermal basal cells of the COX-1-deficient and COX-2-deficient mice, respectively, than in wild-type mice. Papillomas on the COX-deficient mice also displayed the premature onset of keratinocyte terminal differentiation. However, loricrin, a late marker of epidermal differentiation, was not significantly altered, suggesting that it was the early stages of keratinocyte differentiation that were primarily affected by COX deficiency. Because keratin 5, a keratin associated with basal cells, was detected differently in papillomas of COX-1-deficient as compared with COX-2-deficient mice, it appears that the isoforms do not have identical roles in papilloma development. Interestingly, apoptosis, a cellular process associated with nonsteroidal anti-inflammatory drug-induced inhibition of tumorigenesis, was not significantly altered in the epidermis or in papillomas of the COX-deficient mice. Thus, both COX-1 and COX-2 have roles in keratinocyte differentiation, and we propose that the absence of either isoform causes premature terminal differentiation of initiated keratinocytes and reduced tumor formation. 相似文献
54.
Judson MA 《Seminars in respiratory and critical care medicine》2002,23(6):529-541
Sarcoidosis is a multisystem granulomatous disease of unknown cause that primarily affects the lung and lymphatic systems of the body. However, any organ may be affected, including the abdominal organs and gastrointestinal tract. As with other forms of sarcoidosis, abdominal sarcoidosis presents diagnostic, prognostic, and therapeutic dilemmas. This article reviews the various forms of abdominal sarcoidosis, with particular attention given to methods of diagnosis and treatment options. 相似文献
55.
Chooi P Lee Maja J A de Jonge Anne E O'Donnell Kristel L Schothorst Janet Hanwell Jon B Chick Rik A Brooimans Laurel M Adams Daniel W Drolet Johann S de Bono Stan B Kaye Ian R Judson Jaap Verweij 《Clinical cancer research》2006,12(9):2841-2848
PURPOSE: To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients with advanced solid malignancies. EXPERIMENTAL DESIGN: OSI-7836 was initially given as a 60-minute i.v. infusion on day 1 every 21 days. In view of its dose-limiting toxicities, the administration time was amended to a 5-minute bolus, and subsequently, the schedule was amended to weekly for 4 weeks followed by a 2-week rest. Blood and urine samples were collected for pharmacokinetic studies. Analyses of cytokines and lymphocyte subsets were added later in the study to elucidate a mechanism for the severe fatigue and lymphocyte depletion observed in earlier patients. RESULTS: Thirty patients received a total of 61 treatment cycles. Fatigue was the main dose-limiting toxicity. Maximum-tolerated dose was defined as 300 mg/m2 in the 60-minute infusion, (three times per week) schedule; 400 mg/m2 in the 5-minute bolus infusion, (three times per week) schedule; and 100 mg/m2 in the weekly schedule. Other common toxicities were nausea, vomiting, rash, fever, and a flu-like syndrome. There were no clinically significant hematologic toxicities. Following the initial dose, OSI-7836 was eliminated from plasma with a median (range) elimination half-life of 48.3 minutes (22.6-64.8 minutes). Lymphocyte subset analysis showed a significant drop in B cell counts, which persisted to day 14 and beyond. Cytokine analysis showed significant elevations of interleukin-6 and interleukin-10 in all patients who received > or = 200 mg/m2 OSI-7836. Best response was disease stabilization in seven patients. CONCLUSION: OSI-7836 was associated with excessive fatigue, and despite changes in its schedule and duration of administration, we did not observe an improvement in its tolerability. Its potentially selective effect on B lymphocytes could be exploited in further studies in specific hematologic malignancies. 相似文献
56.
Hugo E R Ford Fraser Mitchell David Cunningham David C Farrugia Mark E Hill Charlotte Rees A Hilary Calvert Ian R Judson Ann L Jackman 《Clinical cancer research》2002,8(1):103-109
5-Fluorouracil (5-FU) exerts cytotoxic effects through inhibition of thymidylate synthase (TS) and incorporation of metabolites into RNA. TS inhibition may be greater for infusional 5-FU, with bolus regimens more likely to cause RNA effects. Elevation of plasma 2'-deoxyuridine (dUrd) is a surrogate marker of TS inhibition. Nineteen patients were treated with continuous infusion (CI) 5-FU 300mg/m(2)/day or bolus 5-FU 425mg/m(2)/day plus leucovorin (LV) 20mg/m(2)/day days 1-5. Pretreatment (day 1) and day 2, 3, 4, 5, 8, 15, 22, and 29 plasma samples were assayed for dUrd by reverse-phase high-performance liquid chromatography. In patients treated with bolus 5-FU/LV, dUrd elevation at 24 and 48 h was 235 +/- 125 and 254 +/- 119%, respectively, falling to 138 +/- 58%, 156 +/- 89%, and 92 +/- 25% on days 8, 15, and 22, respectively. dUrd elevation with CI 5-FU was 229 +/- 86% at 24 h and 239 +/- 86, 240 +/- 98%, and 255 +/- 109% at days 15, 22, and 29, respectively. Duration of dUrd elevation was generally less than 8 days for bolus 5-FU/LV. A single dose of raltitrexed (3 mg/m(2)) gave a similar profile to this regimen. ZD9331 (130 mg/m(2), days 1 and 8) gave dUrd elevation for 14 of 21 days, with some recovery prior to day 8. Thus, both 5-FU regimens inhibit TS, and prolonged TS inhibition is achieved by CI 5-FU without significant toxicity. This suggests that the mechanism of antiproliferative toxicity from bolus 5-FU/LV is partly non-TS mediated. These results clarify underlying pharmacodynamic processes and could guide scheduling of 5-FU and TS inhibitors. 相似文献
57.
58.
Mirsalis Jon C.; Tyson C. Kimerly; Loh Erica N.; Steinmetz Karen L.; Bakke James P.; Hamilton Carol M.; Spak Dana K.; Spalding Judson W. 《Carcinogenesis》1985,6(10):1521-1524
We have modified the in vivo-in vitro hepatocyte DNA repairassay for measurement of unscheduled DNA synthesis (UDS) andhepatic cell proliferation in B6C3F1 mice. Dimethylnitros-amineand methylmethane sulfonate produced significant increases inUDS in both rats and mice. 2-Acetylaminofluorene induced a significantincrease in UDS in rats, but not in mice. The mouse hepatocarcinogens,carbon tetrachloride, trichloroethylene, polybrominated biphenylsand 2,6-dichloro-p-phenylenediamine all failed to induce UDSin male and female mice, but all induced significant elevationsin hepatic cell proliferation. Increased cell turnover in theliver may therefore be an important mechanism in hepatocarcinogenicityin the mouse. 相似文献
59.
Jones RL Fisher C Al-Muderis O Judson IR 《European journal of cancer (Oxford, England : 1990)》2005,41(18):2853-2860
Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic. However, the response of these subgroups to chemotherapy is not well documented. In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital. Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified. The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated. Survival according to histological grade was also assessed. A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28–69) and 11% (95%CI; 2–29), P = 0.005. Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28–69) and 18% (95%CI; 8–31). Patients with lower grade tumours had better overall survival. This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours. Further confirmation of these results should be sought by similar analyses of other databases. 相似文献
60.
Lawrence G Leafasia J Sheridan J Hills S Wate J Wate C Montgomery J Pandeya N Purdie D 《Bulletin of the World Health Organization》2005,83(1):34-42
OBJECTIVE: To assess the effects of a 3-year programme aimed at controlling scabies on five small lagoon islands in the Solomon Islands by monitoring scabies, skin sores, streptococcal skin contamination, serology and haematuria in the island children. METHODS: Control was achieved by treating almost all residents of each island once or twice within 2 weeks with ivermectin (160-250 microg/kg), except for children who weighed less than 15 kg and pregnant women, for whom 5% permethrin cream was used. Reintroduction of scabies was controlled by treating returning residents and visitors, whether or not they had evident scabies. FINDINGS: Prevalence of scabies dropped from 25% to less than 1% (P < 0.001); prevalence of sores from 40% to 21% (P < 0.001); streptococcal contamination of the fingers in those with and without sores decreased significantly (P = 0.02 and 0.047, respectively) and anti-DNase B levels decreased (P = 0.002). Both the proportion of children with haematuria and its mean level fell (P = 0.002 and P < 0.001, respectively). No adverse effects of the treatments were seen. CONCLUSION: The results show that ivermectin is an effective and practical agent in the control of scabies and that control reduces the occurrence of streptococcal skin disease and possible signs of renal damage in children. Integrating community-based control of scabies and streptococcal skin disease with planned programmes for controlling filariasis and intestinal nematodes could be both practical and produce great health benefits. 相似文献